Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
BMC Gastroenterol ; 17(1): 34, 2017 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-28259136

RESUMO

BACKGROUND: Polyethylene glycosylated (PEGylated) porcine glucagon-like peptide-2 (pGLP-2) considerably increases half-life and stability compared with the native pGLP-2, but the effective dose for intestinal damage is still unclear. This study aims to evaluate the available dose of polyethylene glycosylated porcine glucagon-like peptide-2 (PEG-pGLP-2), a modified, long-acting form of pGLP-2 in an experimental rat model of ulcerative colitis. METHODS: Thirty-five male rats were randomly assigned into five groups: control, dextran sodium sulphate (DSS), DSS + PEG-pGLP-2(L), DSS + PEG-pGLP-2(M) and DSS + PEG-pGLP-2(H). Rats in control group received only water; other rats were fed with 5% (w/v) DSS and intraperitoneally administered with 12.5, 25 and 100 nmol/kg PEG-pGLP-2 daily for 6 days. RESULTS: Compared with the control treatment, DSS treatment significantly (p < 0.05) decreased body weight change, colonic length, duodenal villus height and expression of zonula occludens-1, whereas significantly (p < 0.05) increased colonic damage score and expression of claudin-1, interleukin (IL)-1, IL-7, IL-10, interferon-γ and tumour necrosis factor (TNF)-α in colon. However, the three doses of PEG-pGLP-2 all reduced these effects; these treatments significantly (p < 0.05) increased body weight change and duodenal villus height, whereas significantly (p < 0.05) decreased colonic damage score and expression of IL-1, IL-7 and TNF-α in colon. Specifically, low-dose (12.5 nmol/kg/d) PEG-pGLP-2 was effective. CONCLUSIONS: These results indicated that PEG-pGLP-2 is a novel and potentially effective therapy for intestinal healing in a relatively low dose.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Colo/efeitos dos fármacos , Peptídeo 2 Semelhante ao Glucagon/administração & dosagem , Mucosa Intestinal/efeitos dos fármacos , Polietilenoglicóis/administração & dosagem , Animais , Peso Corporal/efeitos dos fármacos , Claudina-1/efeitos dos fármacos , Colite Ulcerativa/induzido quimicamente , Citocinas/efeitos dos fármacos , Sulfato de Dextrana , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Duodeno/efeitos dos fármacos , Masculino , Ratos , Proteína da Zônula de Oclusão-1/efeitos dos fármacos
2.
J Dent Res ; 92(6): 518-23, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23576426

RESUMO

UNLABELLED: The gingival epithelium plays a key role in protecting the supporting structures of the teeth from bacteria and their products. In ex vivo experiments, we recently showed that the cytolethal distending toxin (Cdt) from the periodontal pathogen Aggregatibacter actinomycetemcomitans causes extensive damage to gingival tissue. Morphological changes included detachment of the keratinized outer layer, distention of spinous and basal cells in the oral epithelium, disruption of rete pegs, and apparent dissolution of cell junctions. Adherens junctions (zonula adherens) are essential for maintaining barrier function and integrity of gingival epithelium. Therefore, immunohistochemical and RT-PCR analyses of human gingival explants (HGX) and human gingival epithelial cells (HGEC) were utilized for a closer examination of the effects of the Cdt on E-cadherin, the key membrane component of adherens junctions. Although there was some variability among tissue donors, exposure of gingival tissue or isolated epithelial cells to the toxin generally resulted in a pronounced increase in the expression and cytosolic distribution of E-cadherin, accompanied by an increase in levels of the intracellular scaffolding proteins ß-catenin and ß-actin. These results indicate that the Cdt induced substantial remodeling of adherens junctions, with a potential impact on the barrier function of gingival epithelium. ABBREVIATIONS: cytolethal distending toxin (Cdt), 4',6-diamidino-2-phenylindole (DAPI), human gingival epithelial cells (HGEC), human gingival explants (HGX), human gingival fibroblasts (HGF), transepithelial resistance (TER).


Assuntos
Toxinas Bacterianas/efeitos adversos , Gengiva/efeitos dos fármacos , Junções Intercelulares/efeitos dos fármacos , Subunidades Proteicas/efeitos adversos , Actinas/análise , Actinas/efeitos dos fármacos , Junções Aderentes/efeitos dos fármacos , Adulto , Aggregatibacter actinomycetemcomitans , Membrana Basal/efeitos dos fármacos , Membrana Basal/ultraestrutura , Caderinas/análise , Caderinas/efeitos dos fármacos , Adesão Celular/efeitos dos fármacos , Membrana Celular/efeitos dos fármacos , Membrana Celular/ultraestrutura , Células Cultivadas , Claudina-1/análise , Claudina-1/efeitos dos fármacos , Impedância Elétrica , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/ultraestrutura , Gengiva/ultraestrutura , Humanos , Queratinócitos/efeitos dos fármacos , Queratinócitos/ultraestrutura , Doenças Periodontais/patologia , Junções Íntimas/efeitos dos fármacos , Fatores de Tempo , Técnicas de Cultura de Tecidos , beta Catenina/análise , beta Catenina/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA